移植肾CD20<sup>+</sup>淋巴细胞浸润的临床意义

郭君其; 邹毓华; 吴晨光; 郑智勇; 吴卫真; 杨顺良; 余英豪; 谭建明

移植肾CD20⁺淋巴细胞浸润的临床意义

- 1 福建医科大学福总临床医学院泌尿外科(福州, 350025
基金项目:
福建省科技创新平台建设计划(No:2008J1006)

解放军南京军区医学科技创新项目(No:09MA093)

详细信息

通讯作者: 谭建明,E-mail:guojunq2002@yahoo.com.cn

中图分类号: R699.2

收稿日期: 2011-09-15

Clinical significance of the infiltration of CD20-positive lymphocytes in renal allograft pathology

- Department of Urology, Fuzhou General Clinical Medical College of Fujian Medical University, Fuzhou, 350025, China

More Information

Corresponding author: TAN Jianming, E-mail: guojunq2002@yahoo.com.cn

Received Date: 15 September 2011

摘要

摘要: 目的:探讨CD20⁺细胞在移植肾排斥反应中浸润程度与移植肾预后的关系。方法:选取93例肾移植后穿刺患者,肾活检组织标本行CD20免疫组化染色。并对病理结果行半定量分析,根据CD20⁺细胞在肾组织内浸润程度,分为阴性组48例(N组,CD20⁺细胞浸润占肾小管间质面积＜10%)、中度浸润组25例(M组,CD20⁺细胞浸润占肾小管间质面积≥10%＜50%)和重度浸润组20例(H组,CD20⁺细胞浸润占肾小管间质面积≥50%)。分析CD20⁺细胞浸润的程度与移植肾预后的相关性。随访内容包括患者穿刺活检后的临床资料,随访内容包括患者的肌酐、蛋白尿变化及移植肾的生存状况等指标。结果:三组患者在年龄、性别、组织活检时间以及移植的次数均没有明显差异(P＞0.05);穿刺活检后12个月的肌酐N组[(276.79±240.78) μmol/L]低于M组[(360.16±290.30) μmol/L];M组低于H组[(466.50±330.53) μmol/L],P＜0.05;CD20⁺浸润组的患者的4年生存率明显低于阴性组(P＜0.05);穿刺活检后12个月内,N组穿刺后出现蛋白尿的概率明显低于M组和H组(P＜0.05)。结论:CD20⁺细胞在肾移植内浸润的程度与移植肾预后有明显相关性。
- CD20⁺细胞 /
- 移植肾 /
- 穿刺活检
Abstract: Objective:To analyze the infiltration of CD20-positive lymphocytes in the reject reaction of renal allograft and the relations with the graft survival.Method:We examined 93 biopsy samples of renal allograft patients.CD20 was assayed by immunochemistry staining.These cases were divided into three groups according to the degree of CD20 positive cell infiltration with semiquantitative method,Three groups,negative group(＜10％,n=48),moderate infiltration(≥10％,＜50％,n=25)and severe group(≥50％,n=20)in all 93 patients,to analyze the relations between the infiltration of CD20-positive lymphocytes and graft survival.All cases were collected the information of treatment,serum creatinine(SCr),albuminuria and graft surviva1.Result:Three groups have no difference with age,gender,biopsy time and times of transplantation(P＞0.05).In the twelfth month of the following-up,the average SCr of severe group(466.50±330.53μmol/L)was higher than that moderate group[(360.16±290.30)mol/L]P＜0.05;the moderate group was higher than that of negative group[(276.79±240.78)μmol/L]P＜0.05.The graft survival ratio of severe group was lower than that of moderate and negative groups(P＜0.05)in 4 years.The ratio of the biopsy patients with albuminuria of severe group was higher than that of moderate and negative group(P＜0.05).Conclusion:The degree of CD20 positive cell infiltration in the renal allograft was an important factor for evaluating allograft prognosis.
- CD20-positive lymphocytes /
- kidney transplantation /
- aspiration biopsy

HTML全文

参考文献(15)

[1]	郭君其,叶永峰,郑智勇,等.移植肾穿刺活检83例临床病理分析[J].诊断病理学杂志,2007,6:444-446.
[2]	TSAI E W,RIANTHAVORN P,GIERTSON D W,et al.CD20+lymphocytes in renal allografts are as-sociated with poor graft survival in pediatric patients[J].Transplantation,2006,82:1769-1773.
[3]	KAYLER L K,LAKKIS F G,MORGAN C,et al.Acutecellular rejection with CD20-positive lymphoid clusters inkidney transplant patients following lymphocyte depletion[J].Am J Transplant,2007,7:949-954.
[4]	文吉秋,黎磊石,陈劲松,等.CD20阳性细胞和HLA—DR表达对移植肾急性排斥反应预后判断的价值[J].肾脏病与透析肾移植杂志,2007,5:435-440.
[5]	郭君其,黄一亮,吴卫真,等.细胞间黏附分子1与移植肾急性排斥反应[J].中国组织工程研究与临床康复,2009,5:862-864.
[6]	柳金顺,谭建明,吴卫真,等.补体裂解片段C4d在移植肾急性排斥反应中的临床意义[J].中华器官移植杂志,2006,27:221-224.
[7]	SARWAL M,CHUA M S,KAMBHAM N,et al.Molecular heterogeneity in acute renal allograft rejec-tion identified by DNA microarray profiling[J].NEngl J Med,2003,349:125-138.
[8]	HIPPEN B E,DEMATTOS A,COOK W J,et al.As-sociation of CD20+infiltrates with poorer clinicaloutcomes in acute cellular rejection of renal allografts[J].Am J Transplant,2005,5:2248-2252.
[9]	KERJASCHKI D,REGELE H M,MOOSBERGER I,et al.Lymphatic neoangiogenesis in human kidneytransplants is associated with immunologically activelymphocytic infiltrates[J].J Am Soc Nephrol,2004,15:603-612.
[10]	MEIER-KRIESCHE H U,OJO AO,HANSON J A,etal.Increased impact of acute rejection on chronic al-lograft failure in recent era[J].Transplantation,2000,70:1098-1100.
[11]	RACUSEN L C,COLVIN R B,SOLEZ K,et al.Anti-body-mediated rejection criteria:An addition to theBanf 97classification of renal allograft rejection[J].Am J Transplant,2003,3:708-714.
[12]	BOHMIG G A,EXNER M,HABICHT A,et al.Capil-lary CA deposition in kidney allograft:A specificmarker of alloantibody-dependents ftinjury[J].J AmSoe Nephrol,2002,13:1091-1099.
[13]	PESCOVITZ M D.B cells:a rational target in alloanti-body-mediated solid organ transplantation rejection[J].Clin Transplant,2006,20:48-54.
[14]	PESCOVITZ M D.Rituximab,an Anti-CD20mono-clonal antibody:history and mechanism of action[J].Am J Transplant,2006,6:859-866.
[15]	GOURISHANKAR S,TURNER P,HALLORAN P.New developments in immunosuppressive therapy inrenal transplantation[J].Expert Opin Biol Ther,2002,2:483-501.